Supplementary Figure S5: Effective long-term silencing of CD147 by RNAi in TIVE-LT cells in vitro. TIVE-LT cells
were transfected with negative control siRNA (n-siRNA) or CD147-siRNA, then cell lysates were 3 collected at indicated time and protein expression was measured by immunoblots. Lane 1, 3, 5, 7: TIVE-LT + n-siRNA; lane 2, 4, 6, 8: TIVE-LT + CD147-siRNA.
Supplementary Figure S6: Targeting ADAMTS1 significantly suppresses TIVE-LT cell tumorigenesis in vivo. TIVE-LT
cells transfected with n-siRNA or ADAMTS1-siRNA (approximately 5 × 10 5 cells were mixed at a ratio of 1:1 with growth factor-depleted Matrigel) were injected subcutaneously into the right and left flanks of nude mice (3 mice per group), respectively. The mice were observed and measured every 2~3 d for the presence of palpable tumors for 21 d.
